Investing.com - 伯恩斯坦法兴集团周四将安进 (NASDAQ:AMGN)的目标价从350.00美元下调至335.00美元，同时维持对该股票的"优于大市"评级。根据 InvestingPro 数据，该股票目前的市盈率为23.5倍，分析师目标价范围从185美元到405美元不等。

该研究公司强调了安进的强劲销售表现，特别是其Evenity和Imdelltra产品，这些表现使Cantor Fitzgerald模型中的更高估计得到了证实。这一表现促成了安进稳健的股息状况，该公司已连续15年保持股息支付，目前收益率为3.3%。

Biotech company Amgen (NASDAQ:AMGN) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 9.4% year on year to ...

Amgen’s second quarter results outpaced Wall Street’s expectations, with management emphasizing strong demand for its ...

More than one in five UK adults tried to access weight-loss medications in the past year alone, according to a survey by the ...

Currently, the analyst consensus on Amgen is a Moderate Buy with an average price target of $328.83, a 15.51% upside from current levels. In a report released yesterday, Citi also maintained a Hold ...